AVITA Medical to Announce Third Quarter 2025 Financial Results
Rhea-AI Summary
AVITA Medical (NASDAQ: RCEL) will report third quarter 2025 financial results after U.S. market close on Thursday, November 6, 2025. The company will host a conference call and webcast the same day at 1:30 p.m. Pacific Time (Friday, November 7, 2025 at 8:30 a.m. Australian Eastern Daylight Time) to discuss results and recent business highlights.
The live webcast will be available in the Events & Presentations section of AVITA Medical's investor website at ir.avitamedical.com. Telephone participants must register in advance to receive dial-in details and a personal PIN; a replay will be posted on the investor site shortly after the live event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RCEL gained 0.82%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
VALENCIA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2025 financial results after the close of the U.S. financial markets on Thursday, November 6, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 7, 2025, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent business highlights.
The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by telephone, please register in advance to receive dial-in details and a personal PIN using the following link: https://edge.media-server.com/mmc/p/fpry6ovp/. A replay of the webcast will be available shortly after the live event on the Investor Relations website.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the rights to manufacture and exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds, with regulatory clearances in Europe, and excluding RECELL GO, in Australia and Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When will AVITA Medical (RCEL) report Q3 2025 results?
What time is the AVITA Medical (RCEL) earnings call and webcast for Q3 2025?
Where can I watch the AVITA Medical (RCEL) live webcast for Q3 2025?
How do I join the AVITA Medical (RCEL) conference call by phone?
Will a replay of the AVITA Medical (RCEL) Q3 2025 webcast be available?
What will AVITA Medical (RCEL) discuss on the Q3 2025 call?
